161196-85-6

Basic information

• Product Name: 3-methoxy-4-(methoxymethyloxy)benzonitrile
• Synonyms: 3-methoxy-4-(methoxymethyloxy)benzonitrile
• CAS NO: 161196-85-6
• Molecular Weight: 193.202
• Mol File: 161196-85-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-methoxy-4-(methoxymethyloxy)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methoxy-4-(methoxymethyloxy)benzonitrile(161196-85-6)
• EPA Substance Registry System: 3-methoxy-4-(methoxymethyloxy)benzonitrile(161196-85-6)

Safety Data

• Hazardous Substances Data: 161196-85-6(Hazardous Substances Data)

Upstream product

• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 107-30-2 chloromethyl methyl ether 
• 13057-17-5 bromethyl methyl ether 

Downstream Products

• 289903-27-1 (3-Methoxy-4-methoxymethoxy benzyl)carbamic Acid Benzyl Ester 
• 161196-90-3 5-methoxy-2-<3-methoxy-4-(methoxymethyloxy)phenyl>-4-methylnicotinic acid ethyl ester 
• 161196-80-1 2-(4-hydroxy-3-methoxyphenyl)-5-methoxy-4-methylnicotinic acid ethyl ester 
• 112388-85-9 7-hydroxy-2,6-dimethoxyonychine 
• 289903-33-9 2-{[4-(benzyloxycarbonylamino)methyl-2-methoxy]phenoxy}acetic acid 
• 289903-31-7 [4-(Benzyloxycarbonylamino-methyl)-2-methoxy-phenoxy]-acetic Acid Methyl Ester 
• 289903-29-3 benzyl N-(4-hydroxy-3-methoxybenzyl)carbamate 
• 119056-15-4 2-(2-methoxy-4-aminomethylphenoxy)-acetic acid 
• 210918-31-3 3-methoxy-4-methoxymethoxybenzylamine 
• 161196-73-2 β-amino-3-methoxy-4-(methoxymethyloxy)cinnamic acid ethyl ester 

Relevant articles and documents

AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof

The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for treating acute, chronic, inflammatory or neuropathic pains or for treating bladder hypersensitivity.